5MJC BCU 17: Updated Survival Analysis of the EGF104900 Randomized Study of Lapatinib Alone or Combined with Trastuzumab for HER2-Positive Breast Cancer Progressing on Trastuzumab


Updated Survival Analysis of the EGF104900 Randomized Study of Lapatinib Alone or Combined with Trastuzumab for HER2-Positive Breast Cancer Progressing on Trastuzumab

Slides from a presentation at SABCS 2009 and transcribed comments from a recent interview with Mark D Pegram, MD (12/23/09)

Dr Pegram is Full Professor of Medicine and Director for the Translational Research Program at the Braman Family Breast Cancer Research Institute at UM Sylvester Comprehensive Cancer Center in Miami, Florida.

Presentation discussed in this issue:

Blackwell KL et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. San Antonio Breast Cancer Symposium 2009;Abstract 61.

Go to previous Journal Club                                       Go to next Journal Club